About: Molecular characterization of respiratory syncytial viruses infecting children reported to have received palivizumab immunoprophylaxis

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Molecular characterization of respiratory syncytial viruses infecting children reported to have received palivizumab immunoprophylaxis Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Molecular characterization of respiratory syncytial viruses infecting children reported to have received palivizumab immunoprophylaxis
Creator	Edwards, Kathryn Erdman, Dean Griffin, Marie Iwane, Marika Williams, John Durigon, Edison Prill, Mila Hall, Caroline Oliveira, Danielle Staat, Mary Szilagyi, Peter Weinberg, Geoffrey
Source	Elsevier; Medline; PMC
abstract	BACKGROUND: Respiratory syncytial virus (RSV) is a major cause of respiratory infections in children. Palivizumab (PZ) is the only RSV-specific immunoprophylaxis approved by the U.S. Food and Drug Administration. Mutations leading to amino acid substitutions in the PZ binding site of the RSV F protein have been associated with breakthrough RSV infections in patients receiving PZ. OBJECTIVE: To detect PZ resistance conferring mutations in RSV strains from children who received PZ. STUDY DESIGN: Children aged ≤24 months on October 31 who were hospitalized or had outpatient visits for respiratory illness and/or fever during October–May 2001–2008 in 3 US counties were included. PZ receipt was obtained from parent interviews and medical records among children subsequently infected with RSV. Archived nasal/throat swab specimens were tested for RSV by real-time RT-PCR. The coding region of the PZ binding site of the RSV F protein was sequenced using both Sanger and pyrosequencing methods. RESULTS: Of 8762 enrolled children, 375 (4.3%) were tested for RSV and had a history of PZ receipt, of which 56 (14.9%) were RSV-positive and 45 of these had available archived specimens. Molecular typing identified 42 partial F gene sequences in specimens from 39 children: 19 single RSV subgroup A, 17 subgroup B and 3 mixed infections. Nucleotide substitutions were identified in 12/42 (28.6%) RSV strains. PZ resistance mutations were identified in 4 (10.2%) of the 39 children, of which one had documented PZ receipt. CONCLUSIONS: Although RSV PZ resistance mutations were infrequent, most RSV-associated illnesses in children with a history of PZ receipt were not due to strain resistance.
has issue date	2015-01-24(xsd:dateTime)
bibo:doi	10.1016/j.jcv.2015.01.016
bibo:pmid	25766983
has license	no-cc
sha1sum (hex)	a3fffb071de7d5eeb06af3def8945e7a9ff30218
schema:url	https://doi.org/10.1016/j.jcv.2015.01.016
resource representing a document's title	Molecular characterization of respiratory syncytial viruses infecting children reported to have received palivizumab immunoprophylaxis
has PubMed Central identifier	PMC7172275
has PubMed identifier	25766983
schema:publication	J Clin Virol
resource representing a document's body	covid:a3fffb071de7d5eeb06af3def8945e7a9ff30218#body_text
is schema:about of	named entity 'Respiratory syncytial virus' named entity 'throat swab' named entity 'Mutations' named entity 'protein' named entity 'history' named entity 'gene' named entity 'interviews' named entity '2008' named entity 'RESULTS' named entity 'RESPIRATORY ILLNESS' named entity 'SPECIMENS' named entity 'ARCHIVED' named entity 'OUTPATIENT VISITS' named entity 'HOSPITALIZED' named entity 'breakthrough' named entity 'resistance' named entity 'Results' named entity 'documented' named entity 'receipt' named entity 'mutations' named entity 'receiving' named entity 'receipt' named entity 'tested' named entity 'RSV' named entity 'Children' named entity 'outpatient' named entity 'palivizumab' named entity 'RSV' named entity 'real-time RT-PCR' named entity 'RSV' named entity 'binding site' named entity 'RSV' named entity 'medical records' named entity 'receipt' named entity 'U.S.' named entity 'Respiratory syncytial virus' named entity 'bioMérieux' named entity 'gene' named entity 'lower respiratory tract' named entity 'wild-type' named entity 'RSV' named entity 'RT-PCR' named entity 'RSV' named entity 'RSV' named entity 'adenovirus' named entity 'co-infection' named entity 'RSV' named entity 'premature birth' named entity 'RSV' named entity 'influenza, human' named entity 'RSV' named entity 'RSV' named entity 'glycoprotein' named entity 'viruses' named entity 'real-time RT-PCR' named entity 'medical records' named entity 'pyrosequencing' named entity 'viruses' named entity 'Infants born prematurely' named entity 'mixed infections' named entity 'murine' named entity 'RSV' named entity 'metapneumovirus' named entity 'amino acid' named entity 'CDC' named entity 'acute respiratory infections' named entity 'codons' named entity 'RSV' named entity 'prophylaxis' named entity 'naturally occurring'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software